GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Laurus Labs Ltd (BOM:540222) » Definitions » Net Cash per Share

Laurus Labs (BOM:540222) Net Cash per Share : ₹-76.52 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Laurus Labs Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Laurus Labs's Net Cash per Share for the quarter that ended in Mar. 2024 was ₹-76.52.

The historical rank and industry rank for Laurus Labs's Net Cash per Share or its related term are showing as below:

BOM:540222's Price-to-Net-Cash is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.13
* Ranked among companies with meaningful Price-to-Net-Cash only.

Laurus Labs Net Cash per Share Historical Data

The historical data trend for Laurus Labs's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laurus Labs Net Cash per Share Chart

Laurus Labs Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -37.02 -57.86 -65.90 -66.41 -76.52

Laurus Labs Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -66.41 - -73.25 - -76.52

Competitive Comparison of Laurus Labs's Net Cash per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Laurus Labs's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laurus Labs's Price-to-Net-Cash Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Laurus Labs's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Laurus Labs's Price-to-Net-Cash falls into.



Laurus Labs Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Laurus Labs's Net Cash per Share for the fiscal year that ended in Mar. 2024 is calculated as

Net Cash per Share (A: Mar. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(1504.7-42714.6-46.2)/539.159
=-76.52

Laurus Labs's Net Cash per Share for the quarter that ended in Mar. 2024 is calculated as

Net Cash per Share (Q: Mar. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(1504.7-42714.6-46.2)/539.159
=-76.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Laurus Labs  (BOM:540222) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Laurus Labs Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Laurus Labs's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Laurus Labs (BOM:540222) Business Description

Traded in Other Exchanges
Address
Road No. 7, Banjara Hills, 2nd Floor, Serene Chambers, Hyderabad, TG, IND, 500034
Laurus Labs Ltd is a pharmaceutical company based in India. It provides active pharmaceuticals ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services. The entity develops APIs and intermediates for select, high-growth antiretrovirals, Hepatitis C and Oncology. It also manufactures APIs in other therapeutic areas, such as anti-asthma, ophthalmology, anti-diabetics, cardiovascular, proton pump inhibitors, among others. The company has its business presence in India and Outside India of which it derives a majority of revenue from Outside India. It generates revenue from the sale of API, Intermediates and Formulations, Contract research services and others.

Laurus Labs (BOM:540222) Headlines

No Headlines